

# Peter P Toth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/387906/publications.pdf>

Version: 2024-02-01

257  
papers

12,782  
citations

25423

59  
h-index

35168

102  
g-index

262  
all docs

262  
docs citations

262  
times ranked

14487  
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
2	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	1.5	5
3	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	1.0	1
4	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	1.6	8
5	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement <sup>o</sup> . American Journal of Preventive Cardiology, 2022, 9, 100318.	1.3	16
6	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 641-651.	2.3	11
7	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. Journal of Clinical Lipidology, 2022, , .	0.6	0
8	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	4.9	14
9	President's page: ASPC is leading the way in preventive cardiology. American Journal of Preventive Cardiology, 2022, 9, 100321.	1.3	0
10	Step-by-step diagnosis and management of the nocebo/drugcebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	2.9	35
11	Ten things to know about ten cardiovascular disease risk factors " 2022. American Journal of Preventive Cardiology, 2022, 10, 100342.	1.3	34
12	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	1.3	58
13	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATV0000000000000153.	1.1	167
14	ASPC President's Page: Getting back To Basics One Patient at a Time. American Journal of Preventive Cardiology, 2022, , 100350.	1.3	0
15	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus, 2022, 17, 100148.	0.3	4
16	The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 2022, 23, 7326.	1.8	30
17	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	1.4	3
18	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Postgraduate Medicine, 2021, 133, 125-139.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. <i>Postgraduate Medicine</i> , 2021, 133, 140-145.	0.9	8
20	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. <i>Endocrinology</i> , 2021, 162, .	1.4	4
21	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	0.5	14
22	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
23	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.0	0
24	ASPC President's Page: Addressing Unmet Needs in Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100155.	1.3	0
25	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health " ELSA-Brasil. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108747.	1.1	8
26	INCREASED INPATIENT MORTALITY FOR CARDIOVASCULAR PATIENTS DURING THE FIRST WAVE OF THE COVID-19 EPIDEMIC IN NEW YORK. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3042.	1.2	0
27	ASPC President's Page: Advancing and Refining Cardiovascular Disease Prevention. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100194.	1.3	0
28	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	2.7	11
29	Ten things to know about ten imaging studies: A preventive cardiology perspective ( "ASPC top ten) Tj ETQq1 1 0,784314,rgBT /Over	1.3	0
30	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100186.	1.3	4
31	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>BMC Medicine</i> , 2021, 19, 139.	2.3	22
32	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases " A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	1.6	39
33	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. <i>Future Cardiology</i> , 2021, 17, 743-755.	0.5	8
34	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
35	Statin Prescribing and Dosing "Failure Has Become an Option. <i>JAMA Cardiology</i> , 2021, 6, 854.	3.0	1
36	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Celebrating ASPC's achievements and introducing new educational offerings. American Journal of Preventive Cardiology, 2021, 7, 100226.	1.3	0
38	That Myalgia of Yours Is Not From Statin Intolerance. Journal of the American College of Cardiology, 2021, 78, 1223-1226.	1.2	6
39	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology, 2021, 78, 1437-1449.	1.2	13
40	Statins: Then and Now. Methodist DeBakey Cardiovascular Journal, 2021, 15, 23.	0.5	54
41	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.	0.0	0
42	Atherogenesis and Vascular Biology. Contemporary Cardiology, 2021, , 11-34.	0.0	1
43	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGram 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	1.0	9
44	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	1.1	38
45	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	2.3	106
46	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	1.0	9
47	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	0.8	41
48	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	2.2	33
49	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	1.3	34
50	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.4	4
51	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. American Journal of Preventive Cardiology, 2020, 3, 100086.	1.3	10
52	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	1.3	142
53	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). Lipids in Health and Disease, 2020, 19, 237.	1.2	8
54	Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics, 2020, 10, 483.	1.3	45

#	ARTICLE	IF	CITATIONS
55	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100040.	1.3	1
56	Pasta Supplemented with <i>Opuntia ficus-indica</i> Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020, 10, 428.	1.3	17
57	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. <i>Archives of Medical Science</i> , 2020, 16, 1279-1287.	0.4	11
58	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	10
59	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007â€“2014. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100087.	1.3	3
60	Prevalence of US Adults with Triglyceridesâ€“150Âmg/dl: NHANES 2007â€“2014. <i>Cardiology and Therapy</i> , 2020, 9, 207-213.	1.1	35
61	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	1.3	90
62	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	2.0	26
63	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	3.8	103
64	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	2.1	31
65	Effect of Evolocumab on Nonâ€“Highâ€“Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014129.	1.6	25
66	Statin therapy in athletes and patients performing regular intense exercise â€“ Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
67	Cover Image, Volume 22, Issue 3. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	2.2	0
68	Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences. <i>Atherosclerosis</i> , 2020, 303, 53-54.	0.4	1
69	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	2.3	52
70	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
71	Familial Hypercholesterolemia and Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2020, 75, 2694-2697.	1.2	2
72	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <i>European Cardiology Review</i> , 2020, 15, 1-9.	0.7	38

#	ARTICLE	IF	CITATIONS
73	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 90.	0.8	6
74	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.4	9
75	The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100132.	1.3	0
76	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	1.8	34
77	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 754-761.	0.6	10
78	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. <i>Clinical Cardiology</i> , 2019, 42, 908-913.	0.7	10
79	INCREASED RESIDUAL CARDIOVASCULAR RISK IN US VETERANS AND MONERATELY-ELEVATED BASELINE TRIGLYCERIDES AND WELL-CONTROLLED LDL-C LEVELS ON STATINS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1719.	1.2	2
80	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. <i>Journal of Clinical Lipidology</i> , 2019, 13, 634-644.	0.6	32
81	Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 175.	1.2	48
82	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	1.5	14
83	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.	0.6	6
84	Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). <i>American Journal of Cardiology</i> , 2019, 124, 1165-1170.	0.7	5
85	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	1.4	45
86	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	0.6	10
87	Elevated Triglycerides ( $\geq 150$ mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients. <i>CardioRenal Medicine</i> , 2019, 9, 400-407.	0.7	14
88	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. <i>Experimental Biology and Medicine</i> , 2019, 244, 1089-1095.	1.1	8
89	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). <i>Maturitas</i> , 2019, 130, 32-37.	1.0	12
90	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. <i>Diabetes Care</i> , 2019, 42, 2307-2314.	4.3	43

#	ARTICLE	IF	CITATIONS
91	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	1.2	45
92	Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003–2004 to 2013–2014). <i>Obesity</i> , 2019, 27, 309-314.	1.5	94
93	Response to “Trends in Obesity, NHANES 2003–2004 to 2013–2014: Is Waist Circumference Increasing Independently of Body Mass Index?” <i>Obesity</i> , 2019, 27, 1044.	1.5	0
94	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	3.1	90
95	Altix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019, 11, 2580.	1.7	39
96	Elevated Triglycerides ( $\geq 150$ mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 533-538.	1.0	13
97	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. <i>Journal of Clinical Lipidology</i> , 2019, 13, 100-108.	0.6	56
98	Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Cardiology</i> , 2019, 73, 408-415.	0.8	8
99	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	0.8	36
100	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
101	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , 2019, 17, 376-378.	0.8	2
102	Prevalence of United States adults with triglycerides $\geq 135$ mg/dL: NHANES 2007–2014. <i>Cardiology Journal</i> , 2019, 26, 604-606.	0.5	6
103	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	2.6	83
104	Management of Statin Intolerance in 2018: Still More Questions Than Answers. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 157-173.	1.0	130
105	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	0.6	6
106	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. <i>Current Atherosclerosis Reports</i> , 2018, 20, 20.	2.0	62
107	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018, 121, 308-314.	0.7	29
108	Introducing the “Drucebo” effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	2.9	84



#	ARTICLE	IF	CITATIONS
109	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. <i>Journal of the American Heart Association</i> , 2018, 7, e008740.	1.6	81
110	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	0.8	50
111	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1290-1297.e1.	0.6	10
112	Natural approaches in metabolic syndrome management. <i>Archives of Medical Science</i> , 2018, 14, 422-441.	0.4	103
113	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	4.0	31
114	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	0.9	87
115	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	1.0	49
116	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	0.9	5
117	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	1.6	67
118	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	0.6	40
119	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
120	<sc>PCSK9</sc> inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	0.7	71
121	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
122	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
123	Association Between Smoking and Serum GlycA and High-Sensitivity C-Reactive Protein Levels: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
124	Baseline Characteristics of a Retrospective Claims Analysis of Cardiovascular Outcomes and Health Care Resource Utilization and Costs in High-Risk Statin-Treated Patients With Hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 797.	0.6	1
125	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	1.3	45
126	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1152-1160.e2.	0.6	83



#	ARTICLE	IF	CITATIONS
127	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 120, 1521-1527.	0.7	36
128	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1300-1308.	0.6	0
129	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	2.3	38
130	All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe Hypertriglyceridemia. <i>Pancreas</i> , 2017, 46, 57-63.	0.5	8
131	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
132	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	0.9	31
133	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 185.	1.0	16
134	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	1.0	166
135	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016, 3, 645-658.	0.4	58
136	Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	77
137	IMPROVE-IT. <i>Current Opinion in Cardiology</i> , 2016, 31, 426-433.	0.8	16
138	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	3.1	61
139	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1365-1370.	1.2	10
140	Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. <i>Journal of Clinical Lipidology</i> , 2016, 10, 880-890.	0.6	47
141	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016, 15, 22.	1.2	25
142	Statin combination therapy and cardiovascular risk reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	0.5	13
143	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	121
144	Bioresorbable scaffold "A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	0.8	24

#	ARTICLE	IF	CITATIONS
145	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	0.9	71
146	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	0.7	8
147	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	0.7	7
148	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1452-1461.	0.6	13
149	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. <i>International Journal of Cardiology</i> , 2016, 225, 184-196.	0.8	155
150	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.4	142
151	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	0.6	29
152	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brazil). <i>Clinical Cardiology</i> , 2016, 39, 215-222.	0.7	5
153	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.4	26
154	Productivity losses associated with cardiovascular disease: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 759-769.	0.7	38
155	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	1.6	25
156	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016, 165, 867.	2.0	84
157	PCSK9 and Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 3-6.	2.0	5
158	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. <i>Lipids in Health and Disease</i> , 2016, 15, 28.	1.2	36
159	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	3.1	19
160	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. <i>Clinical Therapeutics</i> , 2016, 38, 603-609.	1.1	12
161	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	3.1	60
162	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 41-49.	0.8	64

#	ARTICLE	IF	CITATIONS
163	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
164	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. <i>Clinical Cardiology</i> , 2015, 38, 483-491.	0.7	33
165	Position paper Statin intolerance “an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
166	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.4	139
167	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015, 14, 29.	1.2	44
168	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	0.8	60
169	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	0.6	9
170	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	0.6	5
171	Is the Guideline Process Replicable and, if Not, What Does This Mean?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 3-9.	1.6	2
172	Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	3.1	145
173	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	1.6	41
174	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.4	47
175	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> , 2015, 242, 243-250.	0.4	93
176	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	0.6	56
177	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1204-1211.	0.7	19
178	Recommendations for the Management of Patients with Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 473.	2.0	13
179	Statin intolerance “an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
180	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1873-1875.	1.2	4

#	ARTICLE	IF	CITATIONS
181	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
182	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). Journal of Clinical Lipidology, 2015, 9, 676-683.	0.6	14
183	Analysis of vitamin D levels in patients with and without statin-associated myalgia " A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	0.8	154
184	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	1.0	142
185	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in Pharmacology, 2015, 6, 299.	1.6	92
186	Hot Topics in Primary Care: Familial Hypercholesterolemia in Youth. Journal of Family Practice, 2015, 64, S22-30.	0.2	0
187	Dysfunctional HDL: the journey from savior to slayer. Clinical Lipidology, 2014, 9, 49-59.	0.4	15
188	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midlife: The Very Large Database of Lipids (VLDL-10B). Journal of the American Heart Association, 2014, 3, e000851.	1.6	54
189	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. Annals of Medicine, 2014, 46, 341-352.	1.5	1
190	An Update on the Benefits and Risks of Rosuvastatin Therapy. Postgraduate Medicine, 2014, 126, 7-17.	0.9	14
191	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 453-461.	2.2	64
192	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	0.6	98
193	Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology, 2014, 8, 206-216.	0.6	99
194	Residual macrovascular risk in 2013: what have we learned?. Cardiovascular Diabetology, 2014, 13, 26.	2.7	149
195	HDL Hypothesis: Where Do We Stand Now?. Current Atherosclerosis Reports, 2014, 16, 398.	2.0	24
196	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 353-368.	2.2	61
197	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis, 2014, 237, 790-797.	0.4	16
198	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. BMJ, The, 2014, 348, g3047-g3047.	3.0	23

#	ARTICLE	IF	CITATIONS
199	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	1.0	52
200	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	0.6	11
201	JCL Roundtable: HDL in the primary care setting. <i>Journal of Clinical Lipidology</i> , 2014, 8, 364-372.	0.6	4
202	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.4	39
203	High-density lipoprotein subfractions: current views and clinical practice applications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 329-336.	3.1	42
204	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	0.6	31
205	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
206	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.4	53
207	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
208	Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. <i>Current Vascular Pharmacology</i> , 2014, 12, 653-657.	0.8	43
209	Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.	0.5	24
210	High-density lipoproteins: A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013, 7, 484-525.	0.6	276
211	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2061.	3.8	568
212	Non-HDL Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1960-1965.	1.2	59
213	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. <i>Journal of the American College of Cardiology</i> , 2013, 62, 732-739.	1.2	331
214	Emerging LDL therapies: Mipomersen antisense oligonucleotide therapy in the management of hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, S6-S10.	0.6	32
215	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
216	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36

#	ARTICLE	IF	CITATIONS
217	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	23
218	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. <i>Postgraduate Medicine</i> , 2013, 125, 155-161.	0.9	1
219	Very Large Database of Lipids: Rationale and Design. <i>Clinical Cardiology</i> , 2013, 36, 641-648.	0.7	39
220	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	1.0	28
221	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	0.6	4
222	Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006. <i>Journal of Clinical Lipidology</i> , 2012, 6, 325-330.	0.6	206
223	Glucolipototoxicity and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, xvii-xviii.	1.0	4
224	Epicardial Steatosis, Insulin Resistance, and Coronary Artery Disease. <i>Heart Failure Clinics</i> , 2012, 8, 671-678.	1.0	16
225	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	0.6	19
226	The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 109.	2.7	75
227	Ezetimibe therapy: mechanism of action and clinical update. <i>Vascular Health and Risk Management</i> , 2012, 8, 415.	1.0	169
228	Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2012, 8, 39.	1.0	24
229	Addressing key questions with statin therapy. <i>Journal of Family Practice</i> , 2012, 61, S34-9.	0.2	0
230	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	0.6	483
231	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S9-S17.	0.6	292
232	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, S1-S8.	0.6	406
233	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
234	Antisense therapy and emerging applications for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 441-449.	0.6	24



#	ARTICLE	IF	CITATIONS
235	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	1.0	27
236	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 42-51.	1.0	7
237	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
238	Activation of intracellular signaling systems by high-density lipoproteins. <i>Journal of Clinical Lipidology</i> , 2010, 4, 376-381.	0.6	16
239	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	4.9	42
240	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2010, 6, 1065.	1.0	10
241	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	0.9	5
242	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	2.0	32
243	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease. <i>Journal of Family Practice</i> , 2009, 58, S19-25.	0.2	6
244	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary. <i>Journal of Family Practice</i> , 2009, 58, S41-3.	0.2	2
245	An Urgent Matter. Identifying Your Patients' Cardiovascular Risk and Improving Their Outcomes. Introduction. <i>Journal of Family Practice</i> , 2009, 58, S17-8.	0.2	1
246	When high is low: Raising low levels of high-density lipoprotein cholesterol. <i>Current Cardiology Reports</i> , 2008, 10, 488-496.	1.3	13
247	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) Tj ETQq1 1 0.784314 rgBT (0 therapy for dyslipidemia?. <i>Journal of Clinical Lipidology</i> , 2008, 2, 313-317.	0.6	19
248	High-dose statin therapy: benefits and safety in aggressive lipid lowering. <i>Journal of Family Practice</i> , 2008, 57, S29-36.	0.2	4
249	Torcetrapib and atherosclerosis: what happened and where do we go from here?. <i>Future Lipidology</i> , 2007, 2, 277-284.	0.5	12
250	Making a Case for Quantitative Assessment of Cardiovascular Risk. <i>Journal of Clinical Lipidology</i> , 2007, 1, 234-241.	0.6	19
251	Adiponectin and high-density lipoprotein: a metabolic association through thick and thinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. <i>European Heart Journal</i> , 2005, 26, 1579-1581.	1.0	20
252	The "Good Cholesterol" <i>Circulation</i> , 2005, 111, e89-91.	1.6	75

#	ARTICLE	IF	CITATIONS
253	High-Density Lipoprotein and Cardiovascular Risk. <i>Circulation</i> , 2004, 109, 1809-1812.	1.6	113
254	Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. <i>Clinical Therapeutics</i> , 2004, 26, 1355-1367.	1.1	109
255	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. <i>Current Atherosclerosis Reports</i> , 2003, 5, 341-349.	2.0	93
256	Reverse cholesterol transport: High-density lipoprotein's magnificent mile. <i>Current Atherosclerosis Reports</i> , 2003, 5, 386-393.	2.0	69
257	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. <i>Disease-a-Month</i> , 2001, 47, 365-416.	0.4	23